Gilead Sciences, Inc. $GILD Shares Acquired by Price T Rowe Associates Inc. MD

Key Points

• Price T Rowe Associates Inc. increased its holdings in Gilead Sciences by 314.6%, owning a total of 14,703,103 shares valued at approximately $1.65 billion.
• Gilead Sciences reported $2.01 EPS for the last quarter, surpassing analyst expectations, with revenue up 1.4% from the previous year.
• The company declared a quarterly dividend of $0.79 per share, resulting in an annual yield of 2.7%, scheduled for payment on September 29th.

Price T Rowe Associates Inc. MD lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 314.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,703,103 shares of the biopharmaceutical company's stock after acquiring an additional 11,156,382 shares during the period. Price T Rowe Associates Inc. MD owned 1.18% of Gilead Sciences worth $1,647,484,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in GILD. Brighton Jones LLC lifted its stake in Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock worth $1,326,000 after purchasing an additional 2,450 shares during the last quarter. Harvest Investment Services LLC bought a new stake in Gilead Sciences in the fourth quarter worth about $304,000. MGO One Seven LLC lifted its stake in Gilead Sciences by 70.8% in the fourth quarter. MGO One Seven LLC now owns 11,195 shares of the biopharmaceutical company's stock worth $1,034,000 after purchasing an additional 4,639 shares during the last quarter. Syon Capital LLC lifted its stake in Gilead Sciences by 25.5% in the fourth quarter. Syon Capital LLC now owns 18,079 shares of the biopharmaceutical company's stock worth $1,670,000 after purchasing an additional 3,678 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. bought a new stake in Gilead Sciences in the fourth quarter worth about $158,334,000. Institutional investors own 83.67% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Royal Bank Of Canada raised their price objective on shares of Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research note on Friday, August 8th. Daiwa Capital Markets raised shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price target for the company in a research note on Tuesday, August 19th. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target for the company in a research note on Friday, July 25th. Daiwa America raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. Finally, Truist Financial raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and lifted their price target for the company from $108.00 to $127.00 in a research note on Friday, August 8th. Three research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $115.39.

Gilead Sciences Trading Down 1.2%

Shares of Gilead Sciences stock traded down $1.37 on Friday, hitting $114.77. 5,501,912 shares of the company traded hands, compared to its average volume of 6,776,395. The company has a market cap of $142.41 billion, a PE ratio of 22.86, a PEG ratio of 0.70 and a beta of 0.33. The stock's 50 day moving average price is $112.51 and its 200-day moving average price is $109.08. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 52 week low of $75.91 and a 52 week high of $121.83.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. Gilead Sciences's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. Gilead Sciences's payout ratio is 62.95%.

Insider Buying and Selling at Gilead Sciences

In related news, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $113.94, for a total value of $1,139,400.00. Following the completion of the transaction, the chief executive officer owned 605,725 shares of the company's stock, valued at $69,016,306.50. The trade was a 1.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the completion of the transaction, the insider directly owned 114,168 shares of the company's stock, valued at $13,532,333.04. This trade represents a 19.70% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 82,000 shares of company stock worth $9,339,230. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.